Establishment Labs Holdings Inc. (NASDAQ:ESTA) is reporting third quarter earnings results on Monday 9th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.35 per share from $ 19.05 million in revenue.
For the full year, analysts predict revenues of $ 77.73 million, while looking forward to loss of $ 1.91 per share.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 22.00 million ~ $ 23.00 million
Click Here For More Historical Outlooks Of Establishment Labs Holdings Inc.
Previous Quarter Performance
Establishment Labs Holdings Inc. came out with loss for the second quarter of $ 0.45 per share, from the revenue of $ 10.47 million. The quarterly revenues dropped 51.71 percent compared with the same quarter last year. According to street consensus, ESTA was expected to report 2Q20 loss of $ 0.45 per share from revenue of $ 12.50 million. The top line results fell short of analysts by $ 2.03 million or 16.24 percent.
Stock Performance
On Friday, shares of Establishment Labs Holdings Inc. has traded high as $ 25.50 and has cracked $ 24.74 on the downward trend, reaching $ 25.35 with volume of 7.70 thousand shares.
According to the previous trading day, closing price of $ 25.35, representing a 237.30 % increase from the 52 week low of $ 7.56 and a 14.37 % decrease over the 52 week high of $ 29.78.
The company has a market capital of $ 592.35 million and is part of the Healthcare sector and Medical Devices industry.
Conference Call
Establishment Labs Holdings Inc. will be hosting a conference call at 5:00 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.establishmentlabs.com
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue.
